<DOC>
	<DOCNO>NCT00600340</DOCNO>
	<brief_summary>First-line treatment patient locally recurrent metastatic , HER2-negative breast cancer receive prior chemotherapy locally recurrent metastatic disease .</brief_summary>
	<brief_title>2-arm Trial Paclitaxel Plus Bevacizumab vs. Capecitabine Plus Bevacizumab</brief_title>
	<detailed_description>Arm A : Bevacizumab 10 mg/kg intravenous ( i.v . ) , day 1 15 , every 4 week Paclitaxel 90 mg/m2 , day 1 , 8 15 , every 4 week Arm B : Bevacizumab 15 mg/kg i.v. , day 1 , every 3 week Capecitabine 1000 mg/m² twice-daily , day 1-14 , every 3 week In arm treatment give first disease progression ( PD ) , unacceptable toxicity withdrawal patient consent . For patient stop chemotherapy reason PD ( e.g . toxicity ) treatment give monotherapy PD .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>Written inform consent Age ≥18 year Able comply protocol Histologically cytologically confirm , HER2negative , adenocarcinoma breast measurable nonmeasurable locally recurrent metastatic disease ECOG performance status 02 Life expectancy 12 week Prior ( neo ) adjuvant chemotherapy allow provide last dose chemotherapy 6 month prior randomization , ( neo ) adjuvant Therapy Taxanebased , patient eligible receive last taxane 12 month prior randomization . Prior adjuvant radiotherapy allow part treatment early breast cancer If last fraction radiotherapy occur least 6 month prior randomization . Radiotherapy administer solely relief metastatic bone pain allow prior study entry , last fraction radiotherapy administer ≥ 3 week prior randomization . Adequate leave ventricular ejection function Adequate hematological function Adequate liver function Adequate renal function The use fulldose oral parenteral anticoagulant permit long patient stable level anticoagulation least two week time randomization Previous chemotherapy metastatic locally recurrent breast cancer Concomitant hormonal therapy locally recurrent metastatic disease . Previous hormonal therapy must discontinue least 3 week prior randomization Previous radiotherapy treatment metastatic disease Other primary tumor within last 5 year , except adequately control basal cell carcinoma skin , carcinoma situ cervix . Preexisting peripheral neuropathy NCI CTCAE grade &gt; 2 randomization . Evidence spinal cord compression current evidence CNS History evidence upon physical/neurological examination CNS disease unrelated cancer , unless adequately treat standard medical therapy ( e.g . uncontrolled seizure ) Major surgical procedure , open biopsy significant traumatic injury within 28 day prior randomization , anticipation need major surgery course study treatment Minor surgical procedure , include insertion indwelling catheter , within 24 hour prior randomization Current recent ( within 10 day first dose bevacizumab ) use aspirin clopidogrel Chronic daily treatment History evidence inherit bleed diathesis coagulopathy Uncontrolled hypertension Clinically significant cardiovascular disease , require medication study might interfere regularity study treatment , control medication . Nonhealing wound , active peptic ulcer bone fracture History abdominal fistula grade 4 nongastrointestinal fistula , gastrointestinal perforation intraabdominal abscess within 6 month randomization Active infection require i.v . antibiotic randomization . Pregnant lactating female , Women childbearing potential , use contraception Men agree use contraception Current recent ( within 28 day randomization ) treatment another investigational drug participation another investigational study Clinically significant malabsorption syndrome inability take oral medication Psychiatric disability Requirement concurrent use antiviral agent sorivudine chemically related analogue . Evidence disease , metabolic psychological dysfunction , physical examination finding , clinical laboratory find give reasonable suspicion disease condition contraindicate use investigational drug Known DPD deficiency prior unanticipated severe reaction fluoropyrimidine therapy Known hypersensitivity study drug excipients</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>